Spruce Biosciences Recognized as a Bay Area Best Place to Work
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Spruce Biosciences to Participate in May Investor Conferences
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Spruce lays off 5th of staff in wake of phase 2 hyperplasia fail